written on 27.05.2014
Tags:
,

Targeted Therapy in NSCLC Part IV: ALK

TAGS: ,

In the fourth in this series on targeted therapy in non small cell lung cancer (NSCLC) a new target has emerged recently: anaplastic lymphoma kinase (ALK). Also known as ALK tyrosine kinase receptor or CD246 (cluster of differentiation 246), the ALK gene encodes a receptor tyrosine kinase, which belongs to the insulin receptor superfamily. See […]

Latest Report